Irish health inspectors have uncovered evidence of bad management and untrained medical staff administering electric shock therapy to patients in psychiatric wards around the country. Many of Ireland’s psychiatric wards may be closed as they are “unfit for human habitation.”
Clearly the drug industry needs New Year’s Resolutions–and to honor them better than the Corporate Integrity Agreements with the government it keeps breaking. How about: “We will stop upgrading anxiety to depression, depression to bipolar disorder and bipolar disorder to ‘treatment resistant depression’ to sell drugs. We will admit that studies are beginning to show that the reason depression is sometimes treatment resistant is because it wasn’t depression to begin with but consumer advertising.”
In Illinois, advocates are calling for restrictions on Medicaid’s reimbursement for antipsychotic drugs and for enforcement of rules requiring informed patient consent, among other measures.
Study patients took the anti-seizure drug Neurontin, and researchers measured tons of possible outcomes (like pain with touch, pain with cold, excessive pain with pinpricks, more than a dozen different scales for psychiatric symptoms, and so on). By random chance, if you measure enough outcomes, at least some of them will appear better after drug treatment. When the time came to report the findings, however, the researchers systematically omitted the outcomes on which the drug had no effect—and presented only the data showing benefit. That’s like dealing dozens of hands of poker to yourself but showing only the hand with good cards.
A federal lawsuit has been filed against pharmaceutical giant AstraZeneca for its role in paying Chicago psychiatrist Dr. Michael Reinstein nearly $500,000 over the course of a decade to conduct research and to promote its anti-psychotic drug, Seroquel. Cited in the lawsuit was the fact that Reinstein would continually prescribe roughly double the amount of drugs other psychiatrists would prescribe for the same conditions.
SHARE YOUR STORY/COMMENT: